Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Anemia, Refractory, with Excess of Blasts

ClinicalTrials.gov lists 317 trials for Anemia, Refractory, with Excess of Blasts or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 26.

MeSH D000754 Hemic and Lymphatic Diseases C15 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 67 Phase 1/2 Phase 1/2 37 Phase 2 Phase 2 134 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 24 Phase 4 Phase 4 1 Not applicable Not applicable 22 Observational Observational 26 Phase 1 Phase 1 67 Phase 1/2 Phase 1/2 37 Phase 2 Phase 2 134 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 24 Phase 4 Phase 4 1 Not applicable Not applicable 22 Observational Observational 26

Trials per phase (log scale)

317 of the 317 trials are tagged with Anemia, Refractory, with Excess of Blasts itself; the rest are tagged with a narrower condition beneath it.

Get the Anemia, Refractory, with Excess of Blasts report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Anemia, Refractory, with Excess of Blasts trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Not applicable
  • Observational

Top of scale: 19

1992: 1 trials (Phase 2 1) 1993: 3 trials (Phase 3 1, Phase 2 1, Phase 1 1) 1994: 1 trials (Phase 2 1) 1995: 1 trials (Phase 2/3 1) 1996: 8 trials (Observational 1, Phase 3 2, Phase 2 3, Phase 1 2) 1997: 2 trials (Phase 2 2) 1998: 19 trials (Phase 3 3, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 4) 1999: 17 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 6) 2000: 19 trials (Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 3, Phase 1 7) 2001: 14 trials (Observational 2, Not applicable 1, Phase 2 9, Phase 1/2 1, Phase 1 1) 2002: 14 trials (Not applicable 1, Phase 3 2, Phase 2 4, Phase 1/2 3, Phase 1 4) 2003: 12 trials (Not applicable 2, Phase 2 8, Phase 1 2) 2004: 16 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 7, Phase 1/2 1, Phase 1 5) 2005: 17 trials (Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 7) 2006: 12 trials (Phase 2/3 1, Phase 2 6, Phase 1/2 2, Phase 1 3) 2007: 16 trials (Not applicable 1, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 6) 2008: 7 trials (Observational 1, Not applicable 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2009: 11 trials (Observational 1, Phase 2 7, Phase 1 3) 2010: 12 trials (Phase 3 1, Phase 2 7, Phase 1/2 2, Phase 1 2) 2011: 6 trials (Observational 1, Phase 3 1, Phase 2 2, Phase 1/2 2) 2012: 8 trials (Observational 1, Not applicable 1, Phase 2 5, Phase 1 1) 2013: 10 trials (Observational 3, Not applicable 3, Phase 3 1, Phase 2 2, Phase 1/2 1) 2014: 7 trials (Not applicable 1, Phase 2 3, Phase 1/2 2, Phase 1 1) 2015: 5 trials (Observational 1, Phase 3 2, Phase 2 2) 2016: 5 trials (Observational 1, Not applicable 1, Phase 2 1, Phase 1 2) 2017: 4 trials (Phase 2 2, Phase 1/2 1, Phase 1 1) 2018: 8 trials (Phase 3 1, Phase 2 4, Phase 1/2 2, Phase 1 1) 2019: 6 trials (Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 1) 2020: 9 trials (Observational 3, Not applicable 1, Phase 2/3 1, Phase 2 3, Phase 1 1) 2021: 3 trials (Not applicable 1, Phase 2 2) 2022: 6 trials (Observational 2, Not applicable 1, Phase 2 2, Phase 1 1) 2023: 3 trials (Not applicable 1, Phase 2 2) 2024: 4 trials (Observational 1, Phase 2 1, Phase 1/2 1, Phase 1 1) 2025: 14 trials (Not applicable 2, Phase 2 3, Phase 1/2 6, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 15
2025 14
2024 4
2023 3
2022 6
2021 3
2020 9
2019 6
2018 8
2017 4

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 15 trials starting in 2026 and about 13 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 18 trials still running at the 2026-10-09 snapshot; registered median of 49 months across 229 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Anemia, Refractory, with Excess of Blasts trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 67
Phase 1/2 37
Phase 2 134
Phase 2/3 6
Phase 3 24
Phase 4 1
Not applicable 22
Observational 26

How many Anemia, Refractory, with Excess of Blasts trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 7
Recruiting 37
Active, not recruiting 15
Completed 190
Terminated 46

Showing 5 of 7 statuses.

Start your 14-day trial Email me all 7 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Anemia, Refractory, with Excess of Blasts trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 26
European Organisation for Research and Treatment of Cancer - EORTC 7
National Heart, Lung, and Blood Institute (NHLBI) 7

Which drugs are being tested for Anemia, Refractory, with Excess of Blasts? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 61
Busulfan 42

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 72
Cyclosporine 0.05% 42
Mofetil Mycophenolate 40
Peripheral blood stem cell transplantation 36
Total Body Irradiation 34

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Anemia, Refractory, with Excess of Blasts trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Thrombocytopenia 724 7
Leukopenia 707 1
Neutropenia 692 6
Anemia 542 7
Infection w/ Grade 3 or 4 Neutropenia 352 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Anemia, Refractory, with Excess of Blasts? (18)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial. The Lancet. Haematology 2023 Yes
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009 Yes
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004 Yes
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003 Yes
Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. Bone marrow transplantation 2001 Yes

Showing 5 of 18 publications.

Start your 14-day trial Email me all 18 publications as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Myelodysplastic neoplasm with increased blasts Point prevalence Unknown Worldwide Not stated Unspecified
Myelodysplastic neoplasm with increased blasts Annual incidence 1-9 / 1 000 000 Europe Not stated Unspecified
Myelodysplastic neoplasm with increased blasts Annual incidence 1-9 / 1 000 000 Europe Not stated Exact
Myelodysplastic neoplasm with increased blasts Point prevalence Unknown Worldwide Not stated Exact
Myelodysplastic neoplasm with increased blasts Point prevalence Unknown Worldwide Not stated Exact

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Myelodysplastic neoplasm with increased blasts 86839 Exact Orphadata Science knowledge files, Product 1
Myelodysplastic neoplasm with increased blasts 86839 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages